<DOC>
	<DOCNO>NCT01632007</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety treatment SYR-472 diabetic patient .</brief_summary>
	<brief_title>Double-blind Comparative Study SYR-472</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>1 . The participant outpatient . 2 . The participant sign date write , informed consent form require privacy authorization prior initiation study procedure . 1 . The participant serious cardiac disease , serious cerebrovascular disorder , serious pancreatic hematological disease.ï¼ˆe.g. , subject require hospitalization subject hospitalize within 24 week prior commencement observation period ) 2 . The participant consider ineligible study reason investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>